Home/Pipeline/Recombinant COVID-19 Vaccine (CHO Cell)

Recombinant COVID-19 Vaccine (CHO Cell)

COVID-19 Prevention

MarketedApproved (Conditional)N/A

Key Facts

Indication
COVID-19 Prevention
Phase
Marketed
Status
Approved (Conditional)
Company

About Zhifei Biological Products

Zhifei Biological Products is a Chinese biopharmaceutical leader with a mission to 'guard life and convey health.' The company has achieved significant scale through its successful 'technology & market' dual-drive model, combining a robust proprietary R&D engine with an unparalleled domestic commercialization network. Its strategic includes exclusive partnerships with global giants like Merck and GSK, a deep pipeline across nine technology platforms, and expansion into broader therapeutic areas including metabolic and autoimmune diseases.

View full company profile

Other COVID-19 Prevention Drugs

DrugCompanyPhase
Intranasal COVID VaccineVirpax PharmaceuticalsResearch
COVID-19 Vaccine TrialsDM Clinical ResearchNot Specified
SARS-CoV-2 VaccineEpygen BiotechNot Disclosed
COVAXINBharat BiotechCommercial
iNCOVACCBharat BiotechCommercial
IRT Platform (e.g., COVID-19)Biological MimeticsResearch/Pre-clinical
Replicon RNA COVID-19 VaccineBIKEN GroupPreclinical/Development
Convidecia Air® (XBB.1.5 Variant)CanSino BiologicsApproved
COVID-19 VaccineRecbio TechnologyNot specified
COMIRNATY® (BNT162b2)Fosun PharmaApproved
BBIBP-CorVSinopharmApproved
Recombinant Protein COVID-19 VaccineSinopharmApproved